TMP/SMX was cost-effective only when the likelihood of MRSA infection was very high, likely due to its lack of established activity against GAS. Thus, our analysis suggests that, given our current ...

aureus infection and a 27% MRSA rate), cephalexin monotherapy had the lowest average cost per cure ($175) while clindamycin and TMP/SMX cost $244 and $396, respectively. The base-case cost ...